Close Menu

NEW YORK (GenomeWeb) – For metastatic melanoma, BRAF genotyping is typically performed to determine the best pharmacotherapy, but different genotyping methods can have differing efficiencies and ideal uses, particularly in the case of formalin-fixed, paraffin-embedded samples.

According to a new head-to-head comparison of five BRAF genotyping methods performed at the University of Lorraine and Lorraine Cancer Institute in France, certain PCR-based tests are more suitable than others while immunohistochemistry should only be used as a screening tool.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.